IRIS PubliCatt

Evoli Stampanoni-B, Amelia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.311
EU - Europa 3.507
AS - Asia 848
SA - Sud America 57
AF - Africa 46
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 10
Totale 8.794
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.266
DE - Germania 1.027
SE - Svezia 708
CN - Cina 583
UA - Ucraina 417
IT - Italia 353
IE - Irlanda 224
FR - Francia 206
PL - Polonia 166
GB - Regno Unito 138
IN - India 104
FI - Finlandia 100
TR - Turchia 52
BE - Belgio 39
CI - Costa d'Avorio 32
JP - Giappone 32
NL - Olanda 22
RO - Romania 22
RU - Federazione Russa 20
ES - Italia 19
CA - Canada 17
EC - Ecuador 16
CL - Cile 15
MX - Messico 15
AU - Australia 13
HK - Hong Kong 13
IL - Israele 13
BR - Brasile 11
CH - Svizzera 10
SG - Singapore 10
PE - Perù 8
IR - Iran 7
BZ - Belize 6
CZ - Repubblica Ceca 6
KE - Kenya 6
A2 - ???statistics.table.value.countryCode.A2??? 5
BG - Bulgaria 5
GR - Grecia 5
KR - Corea 5
VN - Vietnam 5
EU - Europa 4
PR - Porto Rico 4
TH - Thailandia 4
CO - Colombia 3
HU - Ungheria 3
IQ - Iraq 3
LK - Sri Lanka 3
PT - Portogallo 3
AR - Argentina 2
AT - Austria 2
GA - Gabon 2
JO - Giordania 2
MD - Moldavia 2
MU - Mauritius 2
MY - Malesia 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
OM - Oman 2
PH - Filippine 2
PK - Pakistan 2
SA - Arabia Saudita 2
A1 - Anonimo 1
AL - Albania 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
BF - Burkina Faso 1
CU - Cuba 1
DK - Danimarca 1
DZ - Algeria 1
KZ - Kazakistan 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MK - Macedonia 1
MT - Malta 1
NG - Nigeria 1
NO - Norvegia 1
SK - Slovacchia (Repubblica Slovacca) 1
UY - Uruguay 1
VE - Venezuela 1
ZA - Sudafrica 1
Totale 8.794
Salva come PNG Salva come JPEG
Città #
Chandler 891
Ashburn 397
Jacksonville 281
San Mateo 230
Dublin 215
Wilmington 155
Ann Arbor 154
Warsaw 143
Nanjing 141
Houston 118
Dearborn 116
Woodbridge 114
New York 97
Cattolica 96
Boston 92
Princeton 71
Redwood City 69
Beijing 64
Lawrence 61
Milan 59
Chicago 53
Nürnberg 53
Fairfield 49
Marseille 49
Seattle 47
Bremen 46
Nanchang 45
Izmir 44
Fuzhou 41
Hangzhou 37
Redmond 37
Brussels 33
Abidjan 32
Shanghai 31
Mountain View 30
Shenyang 27
Norwalk 25
Tianjin 25
Hebei 24
Zhengzhou 24
Boardman 23
Changsha 23
Rome 21
London 20
Kunming 18
Leawood 16
Jiaxing 15
Millbury 15
Cambridge 14
University Park 14
Los Angeles 13
Munich 12
Pune 12
Falls Church 11
Philadelphia 11
Washington 11
Berlin 10
Frankfurt am Main 10
Fremont 10
Hong Kong 10
Dagenham 9
Málaga 9
San Jose 9
Bologna 8
Guangzhou 8
Helsinki 8
Indiana 8
Kraków 8
Saint Louis 8
Tokyo 8
Amsterdam 7
Buffalo 7
Hefei 7
Lancaster 7
Lanzhou 7
Loja 7
Arlington Heights 6
Belize City 6
Iasi 6
Nairobi 6
New Delhi 6
Ningbo 6
San Francisco 6
Augusta 5
Cleja 5
Edinburgh 5
Edmonton 5
Guayaquil 5
Jinan 5
Lima 5
Madrid 5
Mexico City 5
Rzeszów 5
Tel Aviv 5
Toronto 5
Zurich 5
Andover 4
Ban Kho 4
Castellana Grotte 4
Changchun 4
Totale 4.853
Salva come PNG Salva come JPEG
Nome #
Myasthenia gravis 204
International consensus guidance for management of myasthenia gravis: Executive summary 197
Single-centre 40-year results of redo operation for recurrent thymomas. 185
Distinctive clinical and neuroimaging characteristics of longitudinally extensive transverse myelitis associated with aquaporin-4 autoantibodies 141
Novel prognostic groups in thymic epithelial tumors: assessment of risk and therapeutic strategy selection. 136
Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery. 136
Thymoma in patients with MG: characteristics and long-term outcome 128
Thymopoiesis, regulatory T cells, and TCRVbeta expression in thymoma with and without myasthenia gravis, and modulatory effects of steroid therapy 128
When myasthenia gravis is not all. 126
Hypoglossal palsy and coeliac disease: an uncommon presentation for a common disease? 123
Thymectomy in myasthenia gravis: proposal for a predictive score of postoperative myasthenic crisis. 123
Poly-autoimmunity in patients with myasthenia gravis: A single-center experience 120
SFEMG: A piece in the diagnostic puzzle of myasthenia 118
PTPN22 and myasthenia gravis: replication in an Italian population and meta-analysis of literature data 110
T cell repertoire in DQ5-positive MuSK-positive myasthenia gravis patients 109
A b3 type-thymoma in a 7-year-old child with myasthenia gravis 104
Overcoming challenges in the diagnosis and treatment of myasthenia gravis 104
Overcoming challenges in the diagnosis and treatment of myasthenia gravis 102
Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. 100
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study 99
Anti-AChR-negative myasthenia gravis: clinical and immunological features 95
Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis 94
Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders 94
Flow Cytofluorimetric Analysis of Anti-LRP4 (LDL Receptor-Related Protein 4) Autoantibodies in Italian Patients with Myasthenia Gravis 92
Remission of myasthenia gravis with MuSK antibodies during ruxolitinib treatment 92
A Genome-wide Association Study of Myasthenia Gravis 90
An Italian Neurology Outpatient Clinic Facing SARS-CoV-2 Pandemic: Data From 2,167 Patients 90
The difficulty in confirming clinical diagnosis of Myasthenia Gravis in a seronegative patient: a possible neurophysiological approach 87
Thymectomy in myasthenia gravis via original video-assisted infra-mammary cosmetic incision and median sternotomy: long-term results in 180 patients. 85
HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5. 84
3,4-Diaminopyridine may improve myasthenia gravis with MuSK antibodies 83
Determinants of cognitive impairment in elderly myasthenia gravis patients 82
Ocular palsies in the absence of other neurological or ocular symptoms: analysis of 105 cases 82
Multiple paraneoplastic diseases associated with thymoma. 81
Tumour necrosis factor beta gene polymorphisms in myasthenia gravis 80
Response to therapy in myasthenia gravis with anti-MuSK antibody 77
Reliability of SFEMG in diagnosing myasthenia gravis: Sensitivity and specificity calculated on 100 prospective cases. 77
Characterization of B cells in muscle-specific kinase antibody myasthenia gravis 77
Management challenges in muscle-specific tyrosine kinase myasthenia gravis. 76
BAFF serum levels in myasthenia gravis: effects of therapy 75
Diagnostic features and subtyping of thymoma lymph node metastases 75
Long-Lasting Rituximab-Induced Reduction of Specific—But Not Total—IgG4 in MuSK-Positive Myasthenia Gravis 75
Anti-acetylcholinesterase antibodies associate with ocular myasthenia gravis. 73
Myasthenia gravis with presynaptic neurophysiological signs: Two case reports and literature review 73
Thymectomy in myasthenia gravis via original video-assisted infra-mammary cosmetic incision and median sternotomy: long term results in 180 patients. 72
Clinical heterogeneity of seronegative myasthenia gravis 71
Guidelines for treatment of autoimmune neuromuscular transmission disorders. 70
Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: A systematic review and meta-analysis 70
Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: a case series of 22 patients 70
Comment on "Cutting edge: human CD4-CD8- thymocytes express FOXP3 in the absence of a TCR". 69
Prognostic grading after complete resection for thymic malignancies 69
Clinical characteristics and outcome of patients with autoimmune encephalitis: clues for paraneoplastic etiology 69
Rituximab in myasthenia gravis: a "to be or not to be" inhibitor of T cell function 66
Immunosuppressive therapies in myasthenia gravis 64
Acquired myasthenia gravis in childhood. 64
Lower motor neuron involvement in longitudinally extensive transverse myelitis with and without aquaporin-4 antibodies 64
The detection of neural autoantibodies in patients with antiepileptic-drug-resistant epilepsy predicts response to immunotherapy 64
Pattern of ocular involvement in myasthenia gravis with MuSK antibodies 64
Spontaneous recovery from anti-NMDAR encephalitis 63
Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue micro array-based multicenter study 63
Myasthenia gravis with antibodies to MuSK: an update 63
Clinical features and outcome of patients with autoimmune cerebellar ataxia evaluated with the Scale for the Assessment and Rating of Ataxia 62
Positive response to therapy in a patient with a seropositive paraneoplastic cerebellar degeneration and an endometrioid carcinoma of the vesicovaginal septum 61
Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management. 61
Serological Immunoglobulin-Free Light Chain Profile in Myasthenia Gravis Patients 60
Epidemiological evidence for a hereditary contribution to myasthenia gravis: A retrospective cohort study of patients from North America 60
Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: a matter of age? 60
A practical guide to the recognition and management of myasthenia gravis 59
Antibody-phenotype correlation in stiff-person syndrome 59
Risk of cancer in patients with myasthenia gravis 58
Early-onset myasthenia gravis: clinical characteristics and response to therapy 57
Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase 56
Changes in regulatory T cells after rituximab in two patients with refractory myasthenia gravis. 56
SHP2 inhibitor protects AChRs from effects of myasthenia gravis MuSK antibody 56
Human Leukocyte Antigen Class II associations in late-onset Myasthenia Gravis 56
Myasthenia gravis during interferon alfa therapy 55
Familial autoimmune myasthenia gravis with different pathogenetic antibodies 55
EFNS/ENS Guidelines for the treatment of ocular myasthenia. 55
Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis 54
Risk factors for tumor occurrence in patients with myasthenia gravis. 53
An update on Thymectomy in Myasthenia Gravis 53
Minimal manifestation status and prednisone withdrawal in the MGTX trial 53
Course and treatment of myasthenia gravis during pregnancy 52
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. 51
Anti-P110 autoantibodies identify a subtype of "seronegative" myasthenia gravis with prominent oculobulbar involvement 51
In sickness and in health: when myasthenia gravis is a conjugal matter 51
Myasthenia gravis and associated autoimmune diseases 50
Thymoma recurrences in myasthenia gravis patients 50
The tiles make a puzzle but the single tile is not the puzzle: The need for a global assessment of the patient 50
Overcoming challenges in the diagnosis and treatment of myasthenia gravis 50
International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update 49
Imatinib mesylate in thymic epithelial malignancies. 48
MuSK autoantibodies in myasthenia gravis detected by cell based assay-A multinational study 48
Molecular genetic alterations in egfr CA-SSR-1 microsatellite and egfr copy number changes are associated with aggressiveness in thymoma 48
Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis 48
Long-term results of corticosteroid therapy in patients with myasthenia gravis 46
Familial autoimmune myasthenia gravis: report of four families 46
242nd ENMC International Workshop: Diagnosis and management of juvenile myasthenia gravis Hoofddorp, the Netherlands, 1–3 March 2019 46
The detection of neural autoantibodies in patients with antiepileptic-drug-resistant epilepsy predicts response to immunotherapy 45
Benefit and danger from immunotherapy in myasthenia gravis 45
Totale 7.790
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.171
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.171
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019175 0 0 0 0 0 0 0 0 0 31 77 67
2019/20201.148 242 50 54 36 91 86 161 39 80 62 142 105
2020/2021987 66 105 19 99 135 50 135 28 121 52 143 34
2021/20221.290 111 97 32 69 97 45 34 197 62 78 182 286
2022/20232.629 313 361 205 387 155 311 256 217 273 41 70 40
2023/2024908 53 318 47 84 46 163 86 74 11 26 0 0
Totale 8.959